Phylonix Pharmaceuticals has been awarded US Patent 7,041,276, "Methods of screening agents for activity using teleosts."
Inventors listed on the patent are George Serbedzija, Carlos Semino, and Deanna Frost.
According to its abstract, the patent protects methods of screening an agent for activity using teleosts. The patent specifically provides methods of screening an agent for angiogenesis activity, toxic activity, and its effect on cell death in teleosts, the abstract states.
Geron has been awarded US Patent No. 7,041,438, "Use of human embryonic stem cells for drug screening and toxicity testing."
Inventors listed on the patent are Melissa Carpenter, Margaret Inokuma, and Chunhui Xu.
According to its abstract, the patent protects an improved system for culturing human pluripotent stem cells in the absence of feeder cells. The role of the feeder cells can be replaced by supporting the culture on an extracellular matrix, and culturing the cells in a conditioned medium. The patent provides permanent cell lines that can produce conditioned medium on a commercial scale. The patent also discloses methods to genetically alter pluripotent stem cells by introducing the cells with a viral vector or DNA/lipid complex. The system described in the patent allows for bulk proliferation of pluripotent stem cells for use in studying the biology of pluripotent stem cell differentiation, and the production of important products for use in human therapy, the abstract states.
The University of Texas has been awarded US Patent No. 7,043,500, "Subtractive clustering for use in analysis of data."
James Leary is the sole inventor listed on the patent.
According to its abstract, the patent protects a data-analysis system and/or method; for example, a data-mining/data-exploration method that uses subtractive clustering to explore the similarities and differences between two or more multi-dimensional data sets, such as those generated using a flow cytometer, image-analysis system, gene expression-analysis system, or protein microarrays.
Bristol-Myers Squibb has been awarded US Patent No. 7,041,501, "Methods of screening for toxicity of test compounds."
Inventors listed on the patent are Oliver Flint, Frederic Moulin, and Stephen Durham.
According to its abstract, the patent protects methods of screening drug candidates for toxic effects on human cells. The patent also provides methods for determining idiosyncratic toxicity of test compounds, the abstract states.